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Background: Type 1 diabetes mellitus (T1DM) causes progressive destruction of pancreatic beta cells leading to
absolute insulin deficiency. Treatment of T1DM requires insulin, and some evidence suggests that longer acting
insulin analogues might have a higher effectiveness and greater safety profile compared to intermediate-acting
insulin. Our objective is to evaluate the comparative effectiveness, safety, and cost of long-acting insulin versus
intermediate-acting insulin through a systematic review and network meta-analysis.
Design/methods: Studies examining long-acting versus intermediate-acting insulin or placebo preparations for
adult T1DM patients will be included. The primary outcome is glycosylated hemoglobin (A1C), and secondary
outcomes include emergency department and physician visits, hospital admissions, weight gain, quality of life,
microvascular complications (e.g., retinopathy), macrovascular complications (e.g., cardiovascular disease), all-cause
mortality, incident cancers, and cost. We will include experimental [randomized clinical trials (RCTs), quasi-RCTs, non-
RCTs], quasi-experimental (controlled before-after, interrupted time series), observational (cohort), and cost studies,
of any duration of follow-up, conducted during all time periods, and disseminated in any language.
We will conduct comprehensive searches of electronic databases from inception onwards, including MEDLINE,
Cochrane Central Register of Controlled Trials, and EMBASE. We will also search for difficult to locate and
unpublished literature by searching dissertation databases, public health organization websites, and trial registries.
After a calibration exercise using our eligibility criteria and data abstraction forms, two reviewers will screen all
citations, full-text articles, and abstract data in duplicate. Conflicts will be resolved by team discussion. Using a
similar process, the Cochrane Effective Practice and Organization of Care Risk of Bias tool will be used to appraise
the risk of bias of experimental and quasi-experimental studies, while the Newcastle Ottawa Scale will be used to
assess the methodological quality of cohort studies. If feasible and appropriate, we will conduct a random effects
meta-analysis, as well as a network meta-analysis.
Discussion: Our systematic review will be of utility to healthcare providers, policy-makers, T1DM patients and family
members regarding treatment options of long-acting versus intermediate-acting insulin preparations.
Trial registration: PROSPERO registry number: CRD42013003610* Correspondence: sharon.straus@utoronto.ca
1Li Ka Shing Knowledge Institute, St. Michael’s Hospital, 209 Victoria Street,
East Building, Room 716, Toronto, ON M5B 1T8, Canada
5Department of Geriatric Medicine, University of Toronto, 27 Kings College
Cir, Toronto, ON M5S 1A1, Canada
Full list of author information is available at the end of the article
© 2013 Tricco et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Tricco et al. Systematic Reviews 2013, 2:73 Page 2 of 5
http://www.systematicreviewsjournal.com/content/2/1/73Background
Type 1 diabetes mellitus (T1DM) is a chronic condition
usually characterized by an autoimmune destruction of
pancreatic beta cells, leading to absolute insulin deficiency
[1]. T1DM is due to a combination of genetic and en-
vironmental factors [1]. The long-term consequences of
T1DM can be severe and include microvascular complica-
tions, such as retinopathy, neuropathy, and nephropa-
thy, as well as macrovascular complications, including
cardiovascular disease, stroke/transient ischemic attack,
and peripheral vascular disease [1].
The incidence of T1DM varies geographically, with
high rates reported across Europe (4 to 41 per 100,000
people per year) and North America (11 to 25 per
100,000 people per year) [2]. Although T1DM accounts
for a small proportion of all diabetes worldwide (range:
5-10%) [1], the incidence of T1DM is increasing [2].
Some estimates suggest a 2.8% increase in the incidence
of T1DM per year [2].
Since insulin deficiency occurs in T1DM, the treatment
of this condition requires the use of insulin. Basal insulin
replacement can be achieved with human or purified
porcine intermediate-acting insulin, including isophane
insulin (Neutral Protamine Hagedorn; NPH) and zinc
insulin (lente) [3] or with long-acting insulin analogues,
such as glargine and detemir [4]. Long-acting insulin
analogues are more expensive than intermediate-acting
insulin [3], yet have a slower absorption and less intra-
individual variability of action, which is presumed to
improve clinical outcomes [5]. Previous reviews of these
agents have found that long-acting insulin analogues
significantly reduced glycosylated hemoglobin (A1C)
compared to intermediate-acting insulin [4,6,7]. However,
none of these reviews included “real-world” evidence
from study designs beyond randomized clinical trials
(RCTs). For example, evidence from observational studies
(e.g., cohort studies) was not included in these reviews.
As such, our objective is to evaluate the “real-world”
comparative effectiveness, safety, and cost of long-acting
insulin versus intermediate-acting insulin in managing
T1DM through a systematic review and network meta-
analysis.
Methods/design
We compiled a systematic review protocol and registered
it with the PROSPERO database (CRD42013003610).
We used the Preferred Reporting Items for Systematic
Reviews and Meta-analyses Protocols (PRISMA-P) ini-
tiative to guide the reporting of our systematic review
protocol [8].
Eligibility criteria
Experimental studies (RCTs, quasi-RCTs, non-RCTs) and
quasi-experimental studies (interrupted time series, con-trolled before and after studies) including adults (aged ≥18
years) with T1DM of any duration who are administered
long-acting basal insulin analogue preparations (e.g.,
glargine, detemir) compared to each other, intermediate-
acting insulin (e.g., NPH, lente), or placebo will be in-
cluded. We will exclude pre-mixed insulin preparations.
To examine rare adverse events, we will also include
observational (cohort) studies. To examine cost, cost and
cost effectiveness studies will be included.
The primary outcome of interest is A1C. Secondary
outcomes include emergency department (ED) visits (for
hypoglycemia and hyperglycemia), physician visits (for
hypoglycemia and hyperglycemia), hospital admissions
(for hypoglycemia and hyperglycemia), weight gain, quality
of life, microvascular complications (retinopathy, neur-
opathy, nephropathy), macrovascular complications (car-
diovascular disease, stroke/transient ischemic attack,
peripheral vascular disease), all-cause mortality, and in-
cident cancers. We will also assess the cost and cost-
effectiveness of long-acting basal insulin preparations.
Both published and unpublished material will be in-
cluded, as well as those disseminated in any language.
Studies of all durations of follow-up conducted at any
point in time will be included. Our draft eligibility form
is presented in Additional file 1 for screening titles and
abstracts (or citations) and potentially relevant full-text
articles.
Information sources and literature search
The main information sources are electronic databases,
such as MEDLINE, EMBASE, and the Cochrane Central
Register of Controlled Trials. This will be supplemented
by searching for gray literature, as recommended by the
Canadian Agency for Technologies in Health (CADTH)
[9]. For example, we will search public health websites
(e.g., Public Health Agency of Canada, Health Canada),
drug regulatory websites (e.g., Food and Drug Adminis-
tration; FDA), and clinical trial registries (e.g., World
Health Organization International Clinical Trials Search
Portal). We will also search authors’ personal files, contact
insulin manufacturers, scan the reference lists of included
studies and relevant reviews, and contact prolific authors
of T1DM long-acting insulin papers.
An experienced librarian will conduct all of the afore-
mentioned literature searches. A draft search strategy for
the MEDLINE database (OVID interface) is presented
in Additional file 2. Our MEDLINE search strategy will
be peer reviewed by another expert librarian using the
Peer Review of Electronic Search Strategies (PRESS)
checklist [10].
Study selection process
The draft screening criteria presented in Additional file
1 will be calibrated by conducting a pilot-test using a
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All team members will screen these citations using the
eligibility criteria, and conflicts will be discussed. The
eligibility criteria will be revised if deemed necessary by
the team or if low agreement is observed (e.g., a kappa
statistic ≤ 60%) [11]. Two team members will then screen
each citation in duplicate using our online SysRev Tool
[12]. Similarly, the draft eligibility criteria will be calibrated
for screening potentially relevant full-text articles, which
will then be screened by two team members independ-
ently. At both the citation level of screening and full-text
level of screening, conflicts will be resolved through team
discussion.
Data items and data collection process
Data will be abstracted on the following characteristics
at the following levels:
(1)Study-level: study design, year of study conduct,
sample size, setting, country of study conduct, type
of insulin, dosage of insulin;
(2)Patient-level: type and number of patients, age mean
and standard deviation, duration of T1DM, baseline
A1C, co-morbidities; and
(3)Outcome level: A1C, ED visits, physician visits,
quality of life, cost.
We will abstract outcome results for each of the fol-
lowing points in time: 6, 12, 24 months, and the longest
duration of follow-up.
The process for data collection will be similar to the
method used for screening. Namely, we will calibrate
our data collection form on a random sample of 5–10
included studies. Each team member will collect the
data, and the team will meet to discuss conflicts. The
data collection form will be revised, as necessary. Subse-
quently, two team members will conduct all data collec-
tion for each study in duplicate. The team has been
trained to spot duplicate publications (or companion
reports) that use the same group of patients to test a
particular intervention. This is particularly an issue when
meta-analysis is being considered [13]. Furthermore, our
team is trained to contact authors of studies with poorly
reported data or for potentially relevant unpublished
material identified, for example, through conference ab-
stracts or dissertations.
Methodological quality/risk of bias appraisal
The methodological quality of cohort studies will be ap-
praised using the Newcastle-Ottawa Scale [14]. The risk
of bias of experimental and quasi-experimental studies
will be appraised using the Cochrane Effective Practice
and Organisation of Care Risk of Bias Tool [15]. Publi-
cation bias will be assessed using funnel plots [16].Finally, studies reporting harms will be appraised using
the McHarm tool [17].
Synthesis of included studies
Firstly, our systematic review results will be reported by
describing study characteristics, patient characteristics,
and outcome results. We will also describe our literature
search results, as well as the methodological quality and
risk of bias results using tables, figures, and text.
Secondly, we will evaluate whether we have sufficient
data to conduct random-effects meta-analysis [18]. We
will ensure that the 95% confidence intervals can be
derived using a normal distribution. We will also ensure
that the body of literature is sufficiently homogenous in
terms of clinical (e.g., patient characteristics), methodo-
logical (e.g., study design), and statistical (e.g., forest
plot consistency) characteristics. For example, clinicians
on the team will use their clinical insight to assess for
clinical heterogeneity, methodologists on the team will
assess for methodological heterogeneity, and statistical
heterogeneity will be calculated using the I2 statistical
test [19]. If extensive heterogeneity is observed (e.g.,
I2> 75% [19]), we will try to explain this via sub-group
analysis and meta-regression analysis [20]. The meta-
regression analysis will examine the influence of factors
such as baseline A1C values (e.g., < 8% versus ≥ 8%),
study size (e.g., < median versus ≥median), and risk of
bias (e.g., high risk of bias versus low risk of bias on the
random sequence generation item) on the meta-analysis
results. Both meta-analysis and meta-regression analysis
will be dependent upon the availability of data. These
analyses will be conducted using SAS version 9.2 [21].
To make use of all existing data, we will impute missing
measures of variance (e.g., standard deviations, standard
errors, 95% confidence intervals). This will be conducted
using established methods [22]. To ensure that our impu-
tations do not bias our results, we will conduct a sensitiv-
ity analysis, which will entail examining the missing data
under both random and nonrandom assumptions [23].
Finally, we will attempt conducting a network (i.e., mixed
treatment comparisons) meta-analysis. This analysis is
particularly useful when there is a lack of head-to-head
studies or when both relevant head-to-head and stand-
ard treatment controlled studies exist. The network
meta-analysis approach allows the ranking of effective-
ness and safety of different insulin preparations [24].
This analysis will be conducted in WinBUGS [25], and
median rankings (or point estimates) will be calculated
using a random effects model that makes use of all
available direct and indirect data [24]. The degree of
uncertainty for all point estimates will be reported as
95% credible intervals (CIs), calculated using the 2.5 and
97.5 percentiles obtained via Monte Carlo simulation of
100,000 iterations [24]. We will assess model convergence
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statistic [26]. We will first include RCTs in the network
meta-analysis. Subsequently, we will include other experi-
mental studies, quasi-experimental studies, and cohort
studies in the network meta-analysis. The consistency of
results will be examined by comparing the results obtained
via frequentist meta-analysis versus network meta-analysis.
This will also be examined statistically, using methods
reported elsewhere [27,28].
Our meta-analysis results will be tested for their ro-
bustness through sensitivity analyses. For example, we
might look at the impact of including/excluding studies
with high risk of bias or poor methodological quality,
studies with high attrition rates, average adherence
between groups, and inclusion of non-RCTs in the ana-
lyses. Since the network meta-analysis is dependent on
different priors for variance parameters included in the
Bayesian approach [24], we will conduct a sensitivity
analysis on these characteristics as well.
Discussion
The incidence of T1DM is increasing annually, and most
patients with this chronic condition require the use of
insulin. As such, our systematic review results have the
potential to influence a large proportion of the population.
Our results can be used to inform healthcare providers,
policy-makers, T1DM patients, and family members
about the comparative effectiveness, safety, and cost of
long-acting versus intermediate-acting insulin prepara-
tions using real-world evidence.
We will ensure that our results reach our key stake-
holders by conducting rigorous and evidence-based know-
ledge translation strategies. Our review was identified
by Canadian policy-makers as a priority topic of the health
of Canadians. We developed our protocol in response to
their query—a form of integrated knowledge translation.
We will ensure that our results are disseminated to these
policy-makers through dissemination meetings and policy
briefs. We will also translate our results to clinicians and
patients by publishing in open access journals, presenting
at a conference symposium, and utilizing social media.
Additional files
Additional file 1: Draft eligibility criteria.
Additional file 2: Draft MEDLINE literature search.
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